Lipid-rich carcinoma of the breast. A dinicopathological study of 49 cases

Tumori

Volumn 94, Issue 3, 2008, Pages 342-346

  Shi, Peng ^a   Wang, Mingming ^a   Zhang, Qinghui ^a   Sun, Jingzhong ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Adjuvant; Breast; Chernotherapy; Lipid rich carcinoma; Prognostic factor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOPTERIN; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TENIPOSIDE; TRASTUZUMAB; VINCRISTINE;

ADULT; AGED; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST DISCHARGE; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID RICH CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NITROBLUE TETRAZOLIUM TEST; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREATMENT DURATION;

EID: 48249097182     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400309     Document Type: Review

References (12)

1. Ramos CV, Taylor HB: Lipid-rich carcinoma of the breast: a clinicopathologic analysis of 13 examples. Cancer, 33: 812-819, 1974.
2. Aboumrad MH, Horn RC, Fine G: Lipid-secreting mammary carcinoma. Cancer, 16: 521-525, 1963.
3. Mazzella FM, Sieber SC, Braza F: Ductal carcinoma of male breast with prominent lipid-rich component. Pathology, 27: 280-283, 1995.
4. Qu LF, Shi JY, Ma DL: Lipid-secreting carcinoma of the breast without lump: a case report. Natl Med J China, 7: 586, 2004.
5. Varga Z, Robl C, Spycher M, Burger D, Caduff R: Metaplastic lipid-rich carcinoma of the breast. Pathol Int, 48: 912-916, 1998.
6. Xu JM, Song ST, Tang ZM, Liu XQ, Jiang ZF, Zhou L, Li YB, Huang Y: Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer. Breast Cancer Res Treat, 49: 251-259, 1998.
7. Tavassoli FA, Devilee P: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: International Agency for Research on Cancer, pp 41-42, 2003.
8. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME: Etiology of hormone receptordefined breast cancer: A systematic review of the literature. Cancer Epidemiol Biomarkers Prev, 13: 1558-1568, 2004.
9. Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU: Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology, 44: 332-338, 2004.
10. Kaptain S, Tan LK, Chen B: Her-2//neu and breast cancer. Diagn Mol Pathol, 10; 139-152, 2001.
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med, 344; 783-792, 2001.
12. Vogel CL, Cobleigh MA, Tripathy D, Robert NJ, Schoil S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20: 719-726, 2002.